Baseline characteristics according to treatment group
Characteristic . | CHOP . | R-CHOP . |
|---|---|---|
| No. of patients | 231 | 234 |
| Median age, y (range) | 55 (27-78) | 54 (26-80) |
| Male/female, % | 51/49 | 46/54 |
| Stage IV at diagnosis, % | 67 | 66 |
| Bulky disease, more than 10 cm; % | 10 | 15 |
| B symptoms, % | 27 | 26 |
| FLIPI score,*% | ||
| 2 | 33 | 33 |
| 3 or higher | 37 | 37 |
| Time from initial diagnosis, % | ||
| 2 y or less | 48 | 50 |
| More than 2 y | 52 | 50 |
| Prior treatment, % | ||
| 1 regimen | ||
| Single agent | 41 | 39 |
| Polychemotherapy | 41 | 39 |
| 2 regimens | 18 | 22 |
| Best response to prior treatment, % | ||
| Relapse after either CR or PR | ||
| CR | 31 | 33 |
| PR | 52 | 51 |
| Refractory | ||
| SD | 11 | 10 |
| PD | 6 | 6 |
Characteristic . | CHOP . | R-CHOP . |
|---|---|---|
| No. of patients | 231 | 234 |
| Median age, y (range) | 55 (27-78) | 54 (26-80) |
| Male/female, % | 51/49 | 46/54 |
| Stage IV at diagnosis, % | 67 | 66 |
| Bulky disease, more than 10 cm; % | 10 | 15 |
| B symptoms, % | 27 | 26 |
| FLIPI score,*% | ||
| 2 | 33 | 33 |
| 3 or higher | 37 | 37 |
| Time from initial diagnosis, % | ||
| 2 y or less | 48 | 50 |
| More than 2 y | 52 | 50 |
| Prior treatment, % | ||
| 1 regimen | ||
| Single agent | 41 | 39 |
| Polychemotherapy | 41 | 39 |
| 2 regimens | 18 | 22 |
| Best response to prior treatment, % | ||
| Relapse after either CR or PR | ||
| CR | 31 | 33 |
| PR | 52 | 51 |
| Refractory | ||
| SD | 11 | 10 |
| PD | 6 | 6 |
SD indicates stable disease.
Assessed retrospectively.